EA201690965A1 - Транскрипционный рнк-вектор и его применения - Google Patents
Транскрипционный рнк-вектор и его примененияInfo
- Publication number
- EA201690965A1 EA201690965A1 EA201690965A EA201690965A EA201690965A1 EA 201690965 A1 EA201690965 A1 EA 201690965A1 EA 201690965 A EA201690965 A EA 201690965A EA 201690965 A EA201690965 A EA 201690965A EA 201690965 A1 EA201690965 A1 EA 201690965A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- applications
- rna vector
- transcriptional rna
- vector
- transcriptional
- Prior art date
Links
- 230000002103 transcriptional effect Effects 0.000 title abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Abstract
Изобретение в целом относится к улучшенному транскрипционному РНК-вектору, который является крайне пригодным для получения мРНК для терапевтических целей in vivo. Улучшения в векторе, в частности, состоят в наличии энхансера транскрипции и элемента удержания в ядре.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192555 | 2013-11-12 | ||
| PCT/EP2014/074349 WO2015071295A1 (en) | 2013-11-12 | 2014-11-12 | Rna transcription vector and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690965A1 true EA201690965A1 (ru) | 2016-09-30 |
| EA035313B1 EA035313B1 (ru) | 2020-05-27 |
Family
ID=49578161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690965A EA035313B1 (ru) | 2013-11-12 | 2014-11-12 | Транскрипционный днк-вектор и его применения |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10159755B2 (ru) |
| EP (2) | EP3068888B1 (ru) |
| JP (2) | JP6530393B2 (ru) |
| KR (2) | KR102396589B1 (ru) |
| CN (2) | CN105849269B (ru) |
| AU (1) | AU2014350222B2 (ru) |
| CA (2) | CA2929203C (ru) |
| DK (2) | DK3336192T3 (ru) |
| EA (1) | EA035313B1 (ru) |
| ES (2) | ES2666380T3 (ru) |
| HK (1) | HK1226097A1 (ru) |
| HU (2) | HUE058792T2 (ru) |
| IL (1) | IL245596B (ru) |
| MX (1) | MX2016006134A (ru) |
| NO (1) | NO3068888T3 (ru) |
| NZ (1) | NZ720885A (ru) |
| PL (2) | PL3068888T3 (ru) |
| PT (2) | PT3068888T (ru) |
| SG (1) | SG11201603482RA (ru) |
| WO (1) | WO2015071295A1 (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| EP4155409B1 (en) | 2015-08-10 | 2023-12-27 | CureVac Manufacturing GmbH | Method of increasing the replication of a circular dna molecule |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響による親和性細胞抽出 |
| CA3085784A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| BR112021013125A2 (pt) | 2019-01-04 | 2021-09-28 | Etherna Immunotherapies Nv | Vacina de mrna |
| KR20220007850A (ko) | 2019-03-13 | 2022-01-19 | 이더알엔에이 이뮤노테라피스 엔브이 | Mrna 백신 |
| BR112021021262A2 (pt) | 2019-04-26 | 2021-12-21 | Etherna Immunotherapies Nv | Formulação de mrna |
| AU2020301582A1 (en) | 2019-06-27 | 2022-02-03 | Etherna Immunotherapies Nv | Combination therapy |
| BR112022013837A2 (pt) | 2020-01-21 | 2022-09-13 | Etherna Immunotherapies Nv | Nanopartículas lipídicas |
| MX2022009943A (es) * | 2020-02-14 | 2022-10-18 | Etherna Immunotherapies Nv | Vacunas intranasales de arnm. |
| MX2022015690A (es) | 2020-06-11 | 2023-02-22 | Etherna Immunotherapies Nv | Nanoparticulas lipidicas. |
| WO2023146230A1 (ko) * | 2022-01-27 | 2023-08-03 | 에스케이바이오사이언스 주식회사 | 단백질 발현을 위한 mrna와 이를 위한 주형 |
| KR102624969B1 (ko) * | 2023-04-03 | 2024-01-16 | 한국과학기술원 | mRNA 번역 증가를 유도하는 mRNA 3'UTR 서열 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| US5861240A (en) * | 1996-02-28 | 1999-01-19 | The Regents Of The University Of California | Isolated human herpesvirus type 8 sequences and uses thereof |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| EP1259602A1 (en) * | 2000-01-28 | 2002-11-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
| US7468275B2 (en) * | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| US7608699B2 (en) * | 2003-12-29 | 2009-10-27 | Rockefeller University | Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof |
| ES2320909T3 (es) * | 2004-06-04 | 2009-05-29 | Centre National De La Recherche Scientifique (Cnrs) | Farmacos para la prevencion o el tratamiento de inmunodeficiencias, enfermedades autoinmunitarias o para la induccion de tolerancia inmunitaria. |
| JP4964493B2 (ja) * | 2006-04-28 | 2012-06-27 | 株式会社カネカ | 内部リボソーム結合部位を利用した遺伝子組換え全抗体の効率的生産法 |
| ES2573458T3 (es) * | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
| SG10201408162PA (en) * | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| CA2713138A1 (en) * | 2008-02-01 | 2009-08-13 | Ceres, Inc. | Promoter, promoter control elements, and combinations, and uses thereof |
-
2014
- 2014-11-12 US US15/034,048 patent/US10159755B2/en active Active
- 2014-11-12 DK DK18153133.6T patent/DK3336192T3/da active
- 2014-11-12 CA CA2929203A patent/CA2929203C/en active Active
- 2014-11-12 NO NO14799996A patent/NO3068888T3/no unknown
- 2014-11-12 DK DK14799996.5T patent/DK3068888T3/en active
- 2014-11-12 SG SG11201603482RA patent/SG11201603482RA/en unknown
- 2014-11-12 PL PL14799996T patent/PL3068888T3/pl unknown
- 2014-11-12 HU HUE18153133A patent/HUE058792T2/hu unknown
- 2014-11-12 CA CA3191243A patent/CA3191243A1/en active Pending
- 2014-11-12 PT PT147999965T patent/PT3068888T/pt unknown
- 2014-11-12 PL PL18153133T patent/PL3336192T3/pl unknown
- 2014-11-12 NZ NZ720885A patent/NZ720885A/en unknown
- 2014-11-12 AU AU2014350222A patent/AU2014350222B2/en active Active
- 2014-11-12 MX MX2016006134A patent/MX2016006134A/es active IP Right Grant
- 2014-11-12 ES ES14799996.5T patent/ES2666380T3/es active Active
- 2014-11-12 EP EP14799996.5A patent/EP3068888B1/en active Active
- 2014-11-12 PT PT181531336T patent/PT3336192T/pt unknown
- 2014-11-12 HU HUE14799996A patent/HUE038831T2/hu unknown
- 2014-11-12 EA EA201690965A patent/EA035313B1/ru unknown
- 2014-11-12 JP JP2016530224A patent/JP6530393B2/ja active Active
- 2014-11-12 CN CN201480071159.0A patent/CN105849269B/zh active Active
- 2014-11-12 EP EP18153133.6A patent/EP3336192B1/en active Active
- 2014-11-12 KR KR1020217018401A patent/KR102396589B1/ko active IP Right Grant
- 2014-11-12 CN CN202010547507.4A patent/CN111621524A/zh active Pending
- 2014-11-12 KR KR1020167015562A patent/KR102267412B1/ko active IP Right Grant
- 2014-11-12 WO PCT/EP2014/074349 patent/WO2015071295A1/en active Application Filing
- 2014-11-12 ES ES18153133T patent/ES2908268T3/es active Active
-
2016
- 2016-05-10 IL IL24559616A patent/IL245596B/en active IP Right Grant
- 2016-12-15 HK HK16114308A patent/HK1226097A1/zh unknown
-
2018
- 2018-08-21 US US16/106,912 patent/US10864284B2/en active Active
-
2019
- 2019-05-16 JP JP2019092623A patent/JP6900054B2/ja active Active
-
2020
- 2020-11-13 US US17/097,815 patent/US20210060182A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690965A1 (ru) | Транскрипционный рнк-вектор и его применения | |
| EA201690549A1 (ru) | Арилэфиры и их применения | |
| BR112016006319A2 (pt) | inibidores de irak e usos dos mesmos | |
| DK3071696T3 (da) | C/ebp alfa kort aktiverings-rna-sammensætninger og fremgangsmåder til anvendelse | |
| EA201690087A1 (ru) | Новые квиназолиноны как ингибиторы бромодомена | |
| HK1221804A1 (zh) | 貨架層級市場營銷和銷售點富集 | |
| FI20136131A (fi) | Suoja, kaareva elementti ja suojan käyttö | |
| DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme | |
| FI20136314A (fi) | Jäätä murtava alus ja menetelmä jäätä murtavan aluksen käyttämiseksi | |
| DK2947141T3 (da) | Mikroorganismer der fremstiller docosahexaensyre og anvendelse deraf | |
| BR112016010568A2 (pt) | hidrogenação catalítica de nitrilas | |
| FI20135866L (fi) | Mikrobiologinen keratiinin prosessointi | |
| FI20135069L (fi) | Puukappaleen uusi käyttö | |
| EA201501137A1 (ru) | Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac | |
| DK2948143T3 (da) | Anvendelse af phenoxypropylaminforbindelser til behandling af depression | |
| DK2953541T3 (da) | Ikke-invasiv fremgangsmåde til måling af vævsperfusionstilstand | |
| DK3071282T3 (da) | Kateterpunktursæt | |
| FR3007981B1 (fr) | Association d'extrait d'hamamelis virginiana, d'escine, et d'acide ascorbique | |
| EP2786402A4 (en) | PRIMING AND SYNTHESIS OF POINTS BY MECHANOSYNTHESIS | |
| EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
| RU2012134432A (ru) | Антидепрессивное средство | |
| ITUA20164278A1 (it) | COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA | |
| TH1401007648A (th) | การเตรียม การใช้ และรูปแบบของแข็งของกรดโอเบติโคลิค | |
| TH1501002638A (th) | รูปแบบยาที่มีการปลดปล่อยยาแบบออกฤทธิ์เนิ่นของรูโซลิทินิบ | |
| UA33973S (uk) | Бобіна шпагату |